Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 348

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 348
---
 may be changed by the representatives. The following table shows the initial public offering price, underwriting discounts and commissions and proceeds, before expenses, to us. The information assumes either no exercise or full exercise by the underwriters of their over-allotment option.

|                                        |     | Per   
 Share |     | Total          
 Without Option |     | With Option |
|:---------------------------------------|:----|:------|:----|:---------------|:----|:------------|
| Initial public offering price          |     | $     |     | $              |     | $           |
| Underwriting discounts and commissions |     | $     |     | $              |     | $           |
| Proceeds, before expenses, to us       |     | $     |     | $              |     | $           |

We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately $4.0 million. We also have agreed to reimburse the underwriters for up to $35,000 for their FINRA counsel fee. In accordance with FINRA Rule 5110, this reimbursed fee is deemed underwriting compensation for this offering. 233

Over-Allotment Option We have granted an option to the underwriters, exercisable for 30 days after the date of this prospectus, to purchase up to 2,500,000 additional shares at the initial public offering price, less underwriting discounts and commissions. If the underwriters exercise this option, each underwriter will be obligated, subject to the conditions contained in the underwriting agreement, to purchase a number of additional shares proportionate to that underwriter’s initial amount reflected in the above table. No Sales of Similar Securities We, our executive officers and directors and substantially all of our other existing security holders have agreed not to sell or transfer any common stock or securities convertible into or exchangeable or exercisable for common stock, for 180 days after the date of this prospectus without first obtaining the written consent of Leerink Partners LLC, Piper Sandler & Co., and Stifel, Nicolaus & Company, Incorporated on behalf of the underwriters. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly:

| • |     | offer, pledge, sell or contract to sell any common stock; |

| • |     | sell any option or contract to purchase any common stock; |

| • |     | purchase any option or contract to